PAX-101 (IV Suramin)
Autism Spectrum Disorder (ASD)
Key Facts
About PaxMedica
PaxMedica is a focused, clinical-stage biotech advancing PAX-101, an intravenous formulation of the century-old drug suramin, for neurological disorders. The company's strategy is based on the hypothesis that modulating the purinergic signaling pathway can treat core symptoms of Autism Spectrum Disorder (ASD) and Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). Key achievements include completing a Phase 3 trial in ASD and securing Orphan Drug Designation for PAX-101 in FXTAS. Its path forward is defined by advancing its concentrated pipeline through regulatory milestones while navigating the high-risk, high-reward landscape of CNS drug development.
View full company profileAbout PaxMedica
PaxMedica is a focused, clinical-stage biotech advancing PAX-101, an intravenous formulation of the century-old drug suramin, for neurological disorders. The company's strategy is based on the hypothesis that modulating the purinergic signaling pathway can treat core symptoms of Autism Spectrum Disorder (ASD) and Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). Key achievements include completing a Phase 3 trial in ASD and securing Orphan Drug Designation for PAX-101 in FXTAS. Its path forward is defined by advancing its concentrated pipeline through regulatory milestones while navigating the high-risk, high-reward landscape of CNS drug development.
View full company profileAbout PaxMedica
PaxMedica is a focused, clinical-stage biotech advancing PAX-101, an intravenous formulation of the century-old drug suramin, for neurological disorders. The company's strategy is based on the hypothesis that modulating the purinergic signaling pathway can treat core symptoms of Autism Spectrum Disorder (ASD) and Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). Key achievements include completing a Phase 3 trial in ASD and securing Orphan Drug Designation for PAX-101 in FXTAS. Its path forward is defined by advancing its concentrated pipeline through regulatory milestones while navigating the high-risk, high-reward landscape of CNS drug development.
View full company profileTherapeutic Areas
Other Autism Spectrum Disorder (ASD) Drugs
| Drug | Company | Phase |
|---|---|---|
| SCI-210 | SciSparc | Phase II |
| eTNS Platform | NeuroSigma | Unknown |
| CM-AT | Curemark | Phase 3 |
| DT402 | Definium Therapeutics | Phase 2a |
| ML-004 | MapLight Therapeutics | Phase 1 |